TikoMed's drug candidate ILB® inhibited infection of hu

TikoMed's drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action

/PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to...

Related Keywords

Sweden , United States , American , Ola Bjorkman , Richard Hayhurst , Anders Kristensson , Prnewswire Tikomed , Celentyx Ltd , Cold Spring Harbor Laboratory , Yellow Fever , Amyotrophic Lateral Sclerosis , Traumatic Brain Injury , Latin American , Tikomed , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Infection Control , Automotive , Transportation , Rucking Amp Railroad , Clinical Trials Amp Medical Discoveries ,